吸入治療薬における技術革新と成長機会

当レポートでは、吸入治療薬について調査分析し、吸入可能な生物製剤の重要な処方を取り上げ、市場成長を促進または抑制する要因について検証しています。また、開発中のモノクローナル抗体とワクチンのパイプラインを調査し、研究開発動向、提携・共同研究動向、資金調達・投資分析、特許分析、吸入可能な生物製剤の見通しを評価しています。

目次

戦略的必須事項

• なぜ成長はますます困難になっているのか？
• The Strategic Imperative 8（TM）
• 吸入治療薬業界に対する上位3つの戦略的必須事項の影響
• 成長機会がGrowth Pipeline Engine（TM）を促進
• 調査手法

成長機会分析

• 分析範囲
• 吸入生物製剤製剤の必要性
• 吸入ドラッグデリバリー：イントロダクション
• セグメンテーション：吸入用製剤
• 吸入用製剤とドラッグデリバリーシステムの長所と短所
• 吸入可能な生物製剤の新規製剤とドラッグデリバリーシステムの例
• 有望な吸入療法：吸入モノクローナル抗体（mAb）とワクチンの利点
• 成長促進要因
• 成長抑制要因

業界の評価と分析

• 吸入ワクチンとモノクローナル抗体のパイプライン分析
• 臨床開発中のワクチンとモノクローナル抗体
• 主要技術：AttenuBlockプラットフォーム技術（弱毒化生ワクチン候補のコドン脱最適化）
• 主要技術：ナノエマルジョンプラットフォーム（鼻腔内アジュバント技術）

イノベーションエコシステム

• 研究開発動向
• コラボレーションとパートナーシップの動向
• 資金調達と投資の分析
• 特許分析
• 今後のロードマップ

成長機会領域

• 成長機会1：ナノテクノロジーを使用した薬物再利用別ネブライザーソリューションの製造
• 成長機会2：エンドツーエンドのサービスを提供するCDMOとの提携
• 成長機会3：安全な吸入投与のための遺伝子ベースの抗体送達

次のステップ

Nanoparticle-based Formulation to Drive Transformational Growth Across Inhaled Vaccines and Monoclonal Antibodies

Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the main focus for inhalation delivery, but recent R&D and increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.

This Frost & Sullivan study highlights important formulations for inhalable biologics and examines the factors that drive or limit market growth. The research examines the pipeline of monoclonal antibodies and vaccines in development and evaluates R&D trends, partnership and collaboration trends, funding and investment analysis, patent analysis, and the outlook for inhalable biologics. The study identifies significant growth opportunities for industry players in the field.

Questions this study answers:

• 1. What factors drive or limit the industry's growth?

• 2. What are the innovative methods for formulating inhalable biologics?

• 3. What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?

• 4. What are the R&D trends and projected developments of the technologies?

• 5. What are the funding evaluations, patent evaluations, regulatory environments, and trends for partnerships and collaborations for inhalable biologics?

• 6. What are the growth opportunities for technology developers in the inhalable biologics space?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• The Need for Inhalation Biologics Formulation
• Inhalation Drug Delivery-Introduction
• Segmentation-Formulations for Drug Inhalation
• Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
• Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
• Promising Inhalation Therapy-Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
• Growth Drivers
• Growth Restraints

Industry Assessment and Analysis

• Pipeline Analysis of Inhaled Vaccines and mAbs
• Vaccines and mAbs under Clinical Development
• Primary Technologies-AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
• Primary Technologies-Nanoemulsion Platform (Intranasal Adjuvant Technology)

Innovation Ecosystem

• R&D Trends
• Collaboration and Partnership Trends
• Funding and Investment Analysis
• Patent Analysis
• Future Roadmap

Growth Opportunity Universe

• Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
• Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services
• Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer